Genentech/OSI Tarceva sNDA
FDA's Oncologic Drugs Advisory Committee will review on Sept. 13 Genentech/OSI's Tarceva sNDA (21-743/S003) for first-line treatment, in combination with gemcitabine (Lilly's Gemzar), of patients with locally advanced, unresectable or metastatic pancreatic cancer. The estimated user fee deadline for the sNDA is Nov. 2. Tarceva (erlotinib) was approved in November 2004 for locally advanced or metastatic non-small cell lung cancer (1"The Pink Sheet" Nov. 29, 2004, p. 4). The meeting will be at the Holiday Inn in Bethesda, Md. at 8 a.m. [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
OSI Pharmaceuticals' existing partnership with Genentech will be unaffected by the firm's acquisition of Eyetech Pharmaceuticals, CEO Colin Goddard assured investors Aug. 22
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.